000			03835cam a2200409Mi 4500
001			94940
003			ES-MaUEC
005			20230102112639.0
006			m o d
007			cr |n|||||||||
008			161130s2016 sz o 000 0 eng d
020			_a3319458264 _q(electronic bk.)
020			_a9783319458267 _q(electronic bk.)
020			_z3319458256
020			_z9783319458250
035			_a(OCoLC)964530204
040			_aYDX _cYDX _dN$T _dIDEBK _dEBLCP _dGW5XE _dOCLCF _dN$T _dUAB _dOCLCQ _dIOG _dMERER _dESU _dOCLCQ _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dIDB _dU3W _dMERUC _dES-MaUEC _bspa
050		4	_aRC270.8 _bK863 2016 EB
100	1		_aKumar, Piyush.
245	1	0	_aNanomedicine for cancer therapy : _bfrom chemotherapeutic to hyperthermia-based therapy _cPiyush Kumar, Rohit Srivastava.
264		1	_aCham, Switzerland _bSpringer _c2016
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aSpringerBriefs in applied sciences and technology, Nanotheranostics
500			_aSpringerLink _bSpringer Engineering eBooks 2017 English+International
505	0		_aPreface; Contents; 1 Nanomedicine for Cancer Therapy; Abstract; 1 Introduction; 2 Conventional Therapy for Breast Cancer; 2.1 Limitation of Conventional Therapy; 3 Multiple Drug Resistance (MDR); 3.1 Drug Efflux and Decrease in Drug Uptake; 3.2 Alteration in Drug Target (Topoisomerase II); 3.3 Change in Detoxifying Enzyme Such Glutathione S-Transferase and Cytochrome P450; 3.4 Increase in DNA Repair; 3.5 Inhibition of Apoptosis by Disruption of Cell Signalling; 3.6 Therapy with Multiple Drug Delivery; 3.6.1 A: Combination of Two Drug Molecule.
505	8		_a3.6.2 B: Combination a Biologics and a Drug Molecule3.6.3 C: Drug Delivery Through Carrier or Nanomedicine; 4 Application of Nanoparticles in Cancer; 4.1 Types of Carriers (NPs) and Its Role in Nanomedicine for Cancer Therapy; 4.1.1 Organic Nanoparticle; 4.1.2 Inorganic Nanoparticle; 4.1.3 Metallic Nanoparticle; 4.1.4 Hybrid Nanoparticle; 4.1.5 Upconversion Nanoparticle; 5 Targeting or Delivery of NPs to the Cancer Cells; 5.1 Passive Targeting; 5.2 Active Targeting or Ligand-Mediated Targeting; 6 Role of Nanomedicine in Modern Day Cancer Therapy; 6.1 Gene Therapy.
505	8		_a6.1.1 DNA/SiRNA Based Gene Therapy6.2 Photodynamic Therapy; 6.2.1 Mechanism of Photodynamic Therapy; 6.2.2 Nanoparticle-Based Photodynamic Therapy; 6.3 Drug Resistance and Heat; 6.4 Therapy Based Thermal Ablation and Hyperthermia; 6.4.1 Types of Hyperthermia; 6.4.2 Heating Systems for Hyperthermia; 6.4.3 Electromagnetic Fields and Heating System/Equipment for Hyperthermia (Table€6); 6.5 Nanoparticles Based Hyperthermia; 6.6 Nanoparticles Based Magnetic Hyperthermia; 6.7 Nano Radiofrequency Hyperthermia: NRFH; 6.8 Photothermal Therapy (PTT) with Nanoparticles Formulation.
505	8		_a6.8.1 Nanoparticles Mediated Photothermal Therapy6.8.2 Metallic Nanoparticles Mediated PTT; 6.8.3 Dye Encapsulated Nanoparticles Based Photothermal Therapy; 6.9 Nano High Intensity Focussed Ultrasound Hyperthermia (NHIFU); 7 Combinatorial Therapy with Hyperthermia; 7.1 Hyperthermia and Radiation; 7.2 Hyperthermia and Drugs; 7.3 Hyperthermia with Photosensitization; 8 Clinical Trials, Success, and Challenges; 9 Conclusion; 10 Challenges; 11 Prospective; References.
650		7	_aCancer _xTreatment. _2fast _0(OCoLC)fst00845538 _9139308 _0comprobar BNE19900970859
700	1		_aSrivastava, Rohit.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-45826-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017B
998			_b02/2018 _dz _e- _zSI
999			_c94940 _d94940 _x1